Loading organizations...
Immunic Therapeutics is a clinical-stage biotechnology company developing novel oral therapies for neurological and gastrointestinal diseases. It focuses on orally administered small molecules addressing unmet needs in chronic inflammatory and autoimmune conditions. Its pipeline includes Vidofludimus Calcium for multiple sclerosis and IMU-856 for celiac disease, reflecting a specialized immunology approach.
Co-founded by Andreas Muehler in April 2016, Immunic Therapeutics originated from the insight to advance drug development projects to clinical proof-of-concept. This foundational vision aimed to translate scientific discoveries into practical oral therapeutic solutions for conditions lacking effective treatments, leveraging expertise in immunology.
Immunic Therapeutics serves patients with chronic inflammatory and autoimmune diseases like multiple sclerosis and celiac disease, aiming to improve their quality of life with convenient oral treatments. Its mission is to deliver high-quality, safe, and efficacious oral therapies offering comprehensive benefits. The company strives to transform scientific innovation into improved health outcomes globally.
IMTherapeutics has raised $10.0M across 1 funding round.
IMTherapeutics has raised $10.0M in total across 1 funding round.
IMTherapeutics has raised $10.0M in total across 1 funding round.
IMTherapeutics's investors include Jason Dinges, T1D Fund, University of Colorado.
IMTherapeutics has raised $10.0M across 1 funding round. Most recently, it raised $10.0M Series A in October 2019.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 1, 2019 | $10M Series A | Jason Dinges | T1D Fund, University OF Colorado | Announced |
No company named IMTherapeutics appears in current records as a technology company. The query likely refers to Perspective Therapeutics (formerly Im Therapeutics or similar naming evolution), a radiopharmaceutical firm developing image-guided, targeted alpha-particle therapies (TATs) for cancer treatment[1]. It builds Pb-212-based radiotherapies using proprietary targeting peptides conjugated to radioisotopes via a Pb-specific chelator, enabling tumor imaging with Pb-203 followed by alpha-particle delivery with Pb-212 for precise cancer cell destruction[1]. This serves oncology patients and physicians, solving limitations of conventional radiotherapy by delivering high-energy alpha radiation directly to tumors, minimizing healthy tissue damage, reducing resistance, and optimizing patient selection through theranostics[1].
The company targets solid tumors with its platform, emphasizing short-range alpha particles for potent killing efficacy[1]. Growth momentum includes advancing multiple programs leveraging the Pb-203/212 isotope pair, positioning it at the forefront of radiopharmaceutical innovation amid rising demand for targeted therapies[1].
Perspective Therapeutics emerged from advancements in radiopharmaceutical technology, focusing on Pb-212 alpha-particle therapies, though specific founding year, founders, or early traction details are not detailed in available sources[1]. The company's backstory centers on pioneering image-guided TATs, evolving from peptide-based targeting to integrate theranostics for pre-treatment tumor confirmation, marking a pivotal shift toward precision oncology[1].
This humanizes the effort as a response to unmet needs in cancer care, where traditional methods fall short, driving innovation in alpha-emitter delivery systems[1].
Perspective Therapeutics rides the radiopharmaceutical wave, particularly alpha-particle therapies, amid surging investment in precision oncology driven by successes like targeted radioligands[1]. Timing aligns with advances in isotope production and peptide engineering, fueled by market forces such as aging populations, rising cancer incidence, and demand for less invasive treatments over chemotherapy[1].
It influences the ecosystem by advancing TATs, potentially setting standards for theranostics and inspiring hybrid imaging-therapy platforms across biotech[1].
Pipeline expansion in Pb-212 programs signals robust momentum, with AI integration and partnerships likely accelerating clinical trials[1]. Trends like scalable isotope supply and combo therapies with immunotherapy will shape its path, evolving its role from innovator to potential market leader in alpha-emitters. Watch for Phase II/III data validating TAT superiority, tying back to its core mission of treating cancer from the inside out[1].
